secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001104659-25-073929
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B
--------------------------------------------------------------------------------

- Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.
- Adjusted EBITDA $522M (32.7% margin) vs $513M (31.9%) prior year; repaid $345M of long-term debt in Q2.
- Women's Health revenue up 2% ex-FX; fertility business +15% ex-FX; Nexplanon flat ex-FX.
- Biosimilars up 6% ex-FX (Hadlima growth); Established Brands down 4% ex-FX on Atozet LOE in Europe.
- FY 2025 revenue guidance raised to $6.275-6.375B; adj. EBITDA margin guidance affirmed at 31-32%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925073929/0001104659-25-073929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925073929/tm2522571d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-073929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer